BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016; 22(12): 3418-3431 [PMID: 27022224 DOI: 10.3748/wjg.v22.i12.3418] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Zarębska-Michaluk D. Viral hepatitis C treatment shortening - what is the limit? Clin Exp Hepatol 2019;5:265-70. [PMID: 31893236 DOI: 10.5114/ceh.2019.88085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Holzmann I, Tovo CV, Minmé R, Leal MP, Kliemann MP, Ubirajara C, Aquino AA, Araujo B, Almeida PRL. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil. Braz J Infect Dis 2018;22:317-22. [PMID: 30036490 DOI: 10.1016/j.bjid.2018.06.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
3 Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int 2018;38:821-33. [PMID: 28941023 DOI: 10.1111/liv.13596] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
4 Abdurakhmanov DT, Rozina TP, Nikulkina EN, Burnevich EZ, Tanashuk EL, Severov MV, Filatova AL, Milovanova SY, Karpov VV, Moiseev SV. [Antiviral therapy of chronic hepatitis C: 30 years success story]. Ter Arkh 2019;91:110-5. [PMID: 32598621 DOI: 10.26442/00403660.2019.11.000470] [Reference Citation Analysis]
5 Yang N, Sun C, Zhang L, Liu J, Song F. Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1). Front Microbiol 2017;8:2153. [PMID: 29209282 DOI: 10.3389/fmicb.2017.02153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhu X, Wang M, Liu M, Yu X, Huang P. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infection. Per Med 2019. [PMID: 31591934 DOI: 10.2217/pme-2018-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Flisiak R, Zarębska-Michaluk D. Perspectives of hepatitis C virus (HCV) elimination in Poland. Clin Exp Hepatol 2019;5:210-4. [PMID: 31598557 DOI: 10.5114/ceh.2019.87633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
9 Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e41077. [PMID: 27826322 DOI: 10.5812/hepatmon.41077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]